Literature DB >> 31576434

Randomised evaluation of active control of temperature versus ordinary temperature management (REACTOR) trial.

Paul J Young1,2, Michael J Bailey3, Frances Bass4,5, Richard W Beasley6, Ross C Freebairn6,7, Naomi E Hammond4,5, Frank M P van Haren8,9,10, Meg L Harward4, Seton J Henderson11, Diane M Mackle6, Colin J McArthur6,12, Shay P McGuinness6,13, John A Myburgh4, Manoj K Saxena4,14, Anne M Turner6, Steve A R Webb3,15,16, Rinaldo Bellomo3,17.   

Abstract

PURPOSE: It is unknown whether protocols targeting systematic prevention and treatment of fever achieve lower mean body temperature than usual care in intensive care unit (ICU) patients. The objective of the Randomised Evaluation of Active Control of temperature vs. ORdinary temperature management trial was to confirm the feasibility of such a protocol with a view to conducting a larger trial.
METHODS: We randomly assigned 184 adults without acute brain pathologies who had a fever in the previous 12 h, and were expected to be ventilated beyond the calendar day after recruitment, to systematic prevention and treatment of fever or usual care. The primary outcome was mean body temperature in the ICU within 7 days of randomisation. Secondary outcomes included in-hospital mortality, ICU-free days and survival time censored at hospital discharge.
RESULTS: Compared with usual temperature management, active management significantly reduced mean temperature. In both groups, fever generally abated within 72 h. The mean temperature difference between groups was greatest in the first 48 h, when it was generally in the order of 0.5 °C. Overall, 23 of 89 patients assigned to active management (25.8%) and 23 of 89 patients assigned to usual management (25.8%) died in hospital (odds ratio 1.0, 95% CI 0.51-1.96, P = 1.0). There were no statistically significant differences between groups in ICU-free days or survival to day 90.
CONCLUSIONS: Active temperature management reduced body temperature compared with usual care; however, fever abated rapidly, even in patients assigned to usual care, and the magnitude of temperature separation was small. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry Number, ACTRN12616001285448.

Entities:  

Keywords:  Antipyresis; Cooling; Fever; Infection; Paracetamol; Sepsis

Mesh:

Substances:

Year:  2019        PMID: 31576434     DOI: 10.1007/s00134-019-05729-4

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  17 in total

1.  A survey of fever management for febrile intensive care patients without neurological injury.

Authors:  Manoj K Saxena; Naomi E Hammond; Colman Taylor; Paul Young; Michael C Reade; Rinaldo Bellomo; John Myburgh
Journal:  Crit Care Resusc       Date:  2011-12       Impact factor: 2.159

2.  Early peak temperature and mortality in critically ill patients with or without infection.

Authors:  Paul Jeffrey Young; Manoj Saxena; Richard Beasley; Rinaldo Bellomo; Michael Bailey; David Pilcher; Simon Finfer; David Harrison; John Myburgh; Kathryn Rowan
Journal:  Intensive Care Med       Date:  2012-01-31       Impact factor: 17.440

3.  Fever control in critically ill adults. An individual patient data meta-analysis of randomised controlled trials.

Authors:  Paul J Young; Rinaldo Bellomo; Gordon R Bernard; Daniel J Niven; Frederique Schortgen; Manoj Saxena; Richard Beasley; Mark Weatherall
Journal:  Intensive Care Med       Date:  2019-02-11       Impact factor: 17.440

4.  The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.

Authors:  G R Bernard; A P Wheeler; J A Russell; R Schein; W R Summer; K P Steinberg; W J Fulkerson; P E Wright; B W Christman; W D Dupont; S B Higgins; B B Swindell
Journal:  N Engl J Med       Date:  1997-03-27       Impact factor: 91.245

Review 5.  Accuracy of peripheral thermometers for estimating temperature: a systematic review and meta-analysis.

Authors:  Daniel J Niven; Jonathan E Gaudet; Kevin B Laupland; Kelly J Mrklas; Derek J Roberts; Henry Thomas Stelfox
Journal:  Ann Intern Med       Date:  2015-11-17       Impact factor: 25.391

Review 6.  Practice misalignments in randomized controlled trials: Identification, impact, and potential solutions.

Authors:  Katherine J Deans; Peter C Minneci; Robert L Danner; Peter Q Eichacker; Charles Natanson
Journal:  Anesth Analg       Date:  2010-08       Impact factor: 5.108

7.  Effect of cooling on oxygen consumption in febrile critically ill patients.

Authors:  C A Manthous; J B Hall; D Olson; M Singh; W Chatila; A Pohlman; R Kushner; G A Schmidt; L D Wood
Journal:  Am J Respir Crit Care Med       Date:  1995-01       Impact factor: 21.405

Review 8.  Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America.

Authors:  Naomi P O'Grady; Philip S Barie; John G Bartlett; Thomas Bleck; Karen Carroll; Andre C Kalil; Peter Linden; Dennis G Maki; David Nierman; William Pasculle; Henry Masur
Journal:  Crit Care Med       Date:  2008-04       Impact factor: 7.598

9.  Targeted temperature management in intensive care - Do we let nature take its course?

Authors:  Robert Golding; Daniel Taylor; Hannah Gardner; Jonathan N Wilkinson
Journal:  J Intensive Care Soc       Date:  2015-10-01

10.  Fever in adult ICUs: an interrupted time series analysis*.

Authors:  Daniel J Niven; Henry T Stelfox; Reza Shahpori; Kevin B Laupland
Journal:  Crit Care Med       Date:  2013-08       Impact factor: 7.598

View more
  2 in total

1.  Fever therapy in febrile adults: systematic review with meta-analyses and trial sequential analyses.

Authors:  Johan Holgersson; Ameldina Ceric; Naqash Sethi; Niklas Nielsen; Janus Christian Jakobsen
Journal:  BMJ       Date:  2022-07-12

Review 2.  A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.

Authors:  Cassandra L Atzrodt; Insha Maknojia; Robert D P McCarthy; Tiara M Oldfield; Jonathan Po; Kenny T L Ta; Hannah E Stepp; Thomas P Clements
Journal:  FEBS J       Date:  2020-06-16       Impact factor: 5.622

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.